| abstract |
The present application discloses compounds according to general formula I, wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful for modulating the activity of BTK and treating diseases associated with excessive BTK activity. The compounds are further useful for treating inflammatory and autoimmune diseases associated with abnormal B cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing a compound of Formula I and at least one carrier, diluent or excipient. |